Skip to main content

Performing Enterra Therapy in ASC’s

(58:01)

Michael Hughes, MD discusses recent Medicare coverage expansion for Enterra Therapy in the ASC setting, including clinical data, patient and practice considerations, ASC readiness, surgical workflow, and practical implementation insights. Watch the recording to learn how your ASC can prepare to offer Enterra Therapy for appropriate gastroparesis patients.

Watch video

Michael Hughes, MD

Vanguard Surgical LLC

IMPORTANT SAFETY INFORMATION

Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.

HUMANITARIAN DEVICE

Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?